2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6274 ClonoSEQ based ctDNA-MRD platform in predicting relapse after front-line DLBCL treatment and potential role of quantitative residual clonal sequence burden

Shibhani Rajanna, MD, Jaeil Ahn2, Andre Goy, MD3, Lori A Leslie, MD4, Tatyana Feldman, MD5, Andrew Ip, MD, MS6
1 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
2 Georgetown University, Washington, DC, District of Columbia, United States
3 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
4 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
5 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
6 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States

Introduction: 

Diffuse large B-cell lymphoma (DLBCL) has 30 to 40% of patients (pts) experiencing relapsed or refractory disease after front-line chemoimmunotherapy. End of treatment (EOT) PET/CT is the gold standard to assess disease status but is limited in its sensitivity for remission at EOT. Next generation sequencing of immunoglobulin (Ig) gene rearrangements is widely used for measurable residual disease (MRD) in various hematological malignancies. Circulating tumor DNA(ctDNA) guided MRD is now included in NCCN guidelines for pts with positive EOT PET/CT results and improves outcome prediction in DLBCL. We aim to study real-world performance of a clonal Ig gene rearrangement based ctDNA-MRD assay (ClonoSEQ) in pts after first line therapy for DLBCL, regardless of PET/CT result.

Methods:

We conducted a single-center retrospective cohort study of DLBCL pts treated with frontline chemoimmunotherapy who had MRD assessment using the ClonoSEQ assay, beginning from March 2025. Clinical data including age, disease characteristics, treatment, EOT PET/CT response, and survival outcomes were abstracted from the electronic medical record. MRD positivity was defined as detection of > 0 residual clonal sequences per 1 mL of plasma by ClonoSEQ.  Baseline characteristics were compared between ctDNA-MRD-positive (MRDpos) and ctDNA-MRD-negative (MRDneg) groups. Progression free survival (PFS) and overall survival (OS) were estimated for each patient and stratified by MRD positivity. MRDpos pts were further stratified by residual clonal sequence count (< 1 vs. ≥ 1). PFS and OS were estimated using the Kaplan-Meier method and compared between groups using the log-rank test. Median follow-up was calculated using the reverse Kaplan-Meier method. A two-sided P-value <0.05 was considered statistically significant.

Results:

Among pts with DLBCL who received front-line chemoimmunotherapy, 42 pts had available ctDNA-MRD ClonoSEQ assays and were included in our study.  The mean age was 65.7 years, 23 (56%) were male, 16 (38%) had IPI 3 or greater, 8 (19%) had double-hit lymphoma and 11 (26%) had bulky disease. 33 (79%) had a complete response (CR) by PET. Frontline therapies included hyperCVAD in 10 (24%), PolaRCHP in 8 (19%), RCHOP in 5 (12%), BiTE combination regimens in 5 (12%), da-EPOCH-R or R2CHOP in 2 (5%), and other modified non-anthracycline based regimens in 12 (28%) pts. 

9 (21%) pts were MRDpos at EOT. MRDpos and MRDneg groups did not differ in terms of age, gender, double-hit status or front-line therapy. There was a trend, however, in bulky disease pts , 4 (44%) vs 7 (21%), having higher incidence of MRDpos status at EOT. MRD status in all patients was significantly associated with EOT response (P<0.05) by PET/CT. 30 (91%) of those with MRDneg and 4 (44%) with MRDpos experienced CR at EOT by PET/CT.  All 4 pts with MRDpos, yet in CR by PET/CT, relapsed.  Three out of these 4 had baseline bulky disease and  relapsed within 6 months.

12-month PFS was significantly higher in MRDneg pts (93.7%) compared to MRDpos pts (21.4%) (p<0.001). OS did not differ between the groups (p=0.508).
Quantitative residual clonal sequence burden demonstrated a trend toward further PFS stratification. The 6-month PFS rate was 94.6% in pts harboring <1 residual clonal sequence per 1 mL of plasma, compared to 75% in patients with ≥1 residual clonal sequence (p=0.37). In addition, within the MRDpos subgroup (n=9), median PFS with residual clonal sequence burden of less than 1 (n=5) was significantly higher (14.7 months) compared to those with ≥1 (n=4) (6.6 months) (P < 0.05).

Conclusion:

In this single-center retrospective study, we evaluated the prognostic value of ctDNA-MRD assessed by ClonoSEQ for EOT response for front-line DLBCL pts. MRD positivity was associated with substantially lower 12-month PFS (21% vs 94%) and a lower proportion of CR (44% vs 91%) by PET/CT at EOT.  Notably, all pts in CR at EOT PET/CT with MRDpos relapsed, with the majority having baseline bulky disease. Furthermore, quantitative ctDNA-MRD appeared to provide additional prognostic information beyond binary MRD status with higher residual clonal burden (>1 sequence per mL plasma) showing a trend towards shorter median PFS.  We acknowledge these findings are limited by sample size and as a single-center retrospective study. Further investigation is needed to understand the best prognostic use or therapeutic intervention when integrating EOT PET/CT with MRDpos results for DLBCL pts.

Shibhani Rajanna, MD: No relevant conflicts of interest to declare.